852180-96-2

Basic information

• Product Name: 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BROMO-1-METHYL-
• Synonyms: 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BROMO-1-METHYL-;2-broMo-1-Methyl-1H-iMidazole-5-carboxylic acid
• CAS NO: 852180-96-2
• Molecular Formula: C5H5BrN2O2
• Molecular Weight: 205.02
• Mol File: 852180-96-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BROMO-1-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BROMO-1-METHYL-(852180-96-2)
• EPA Substance Registry System: 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 2-BROMO-1-METHYL-(852180-96-2)

Safety Data

• Hazardous Substances Data: 852180-96-2(Hazardous Substances Data)

Usage

Structure

1H-imidazole ring with a 5-carboxylic acid, 2-bromo, and 1-methyl groups attached

Derivative of

Imidazole

Contains

Carboxylic acid and bromomethyl group

Usage

Commonly used in the pharmaceutical industry for the synthesis of various drugs and bioactive molecules

Possesses

Potential biological activities

Utilized as

A building block in organic synthesis

Versatile compound with

Various potential applications in medicinal chemistry and drug development

Upstream product

• 17289-20-2 methyl 1-methyl-1H-imidazole-5-carboxylate 
• 120781-02-4 2-bromo-3-methyl-3H-imidazole-4-carboxylic acid methyl ester 

Relevant articles and documents

NOVEL PYRIDAZINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS

The present invention relates to novel pyridazine compounds of formula I as well as processes and intermediates for preparing pyridazine compounds of formula I, and also to active compound combinations comprising them, to compositions comprising them and

An Angle on MK2 Inhibition—Optimization and Evaluation of Prevention of Activation Inhibitors

The mitogen-activated protein kinase p38α pathway has been an attractive target for the treatment of inflammatory conditions such as rheumatoid arthritis. While a number of p38α inhibitors have been taken to the clinic, they have been limited by their efficacy and toxicological profile. A lead identification program was initiated to selectively target prevention of activation (PoA) of mitogen-activated protein kinase-activated protein kinase 2 (MK2) rather than mitogen- and stress-activated protein kinase 1 (MSK1), both immediate downstream substrates of p38α, to improve the efficacy/safety profile over direct p38α inhibition. Starting with a series of pyrazole amide PoA MK2 inhibitor leads, and guided by structural chemistry and rational design, a highly selective imidazole 9 (2-(3′-(2-amino-2-oxoethyl)-[1,1′-biphenyl]-3-yl)-N-(5-(N,N-dimethylsulfamoyl)-2-methylphenyl)-1-propyl-1H-imidazole-5-carboxamide) and the orally bioavailable imidazole 18 (3-methyl-N-(2-methyl-5-sulfamoylphenyl)-2-(o-tolyl)imidazole-4-carboxamide) were discovered. The PoA concept was further evaluated by protein immunoblotting, which showed that the optimized PoA MK2 compounds, despite their biochemical selectivity against MSK1 phosphorylation, behaved similarly to p38 inhibitors in cellular signaling. This study highlights the importance of selective tool compounds in untangling complex signaling pathways, and although 9 and 18 were not differentiated from p38α inhibitors in a cellular context, they are still useful tools for further research directed to understand the role of MK2 in the p38α signaling pathway.

AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS

The present invention provides a compound of formula I: and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.